This VJHemOnc podcast introduces the first edition of Myeloid Monthly, focusing on key developments in myeloid malignancies. Amer Zeidan, MD, Yale University, New Haven, CT, is joined by Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Sanam Loghavi, MD, MD Anderson Cancer Center, Houston, TX, to discuss breaking updates from the Classification Advancement Meeting (CAM), held in Chicago in March 2026.

The panel explores the evolving classification of myeloid neoplasms, including the shift from morphology to molecular genetics, key differences between the WHO and ICC systems, and areas of ongoing debate such as MDS, AML, and overlap syndromes. They also discuss the process of harmonising these frameworks, the clinical implications for diagnosis, trial design, and patient care, and how CAM recommendations are expected to inform a future unified WHO classification.

This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents.

Experts discuss the growing importance of donor germline genetics, updated guidance for Hodgkin lymphoma transplantation, the shifting role of CAR T‑cell therapy in non‑Hodgkin lymphoma, and how measurable residual disease (MRD) is shaping transplant decisions and post‑transplant care.

Overall, the episode highlights how these developments are improving personalization and outcomes in haemopoietic stem cell transplantation.

This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the potential of MRD as a surrogate endpoint in AML, while Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, presents supporting evidence from large registry analyses.

Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, highlights the integration of MRD into risk stratification, while Wendy Stock, MD, University of Chicago Medical Center, Chicago, IL, reviews MRD detection methods, emerging technologies, and practical implementation in ALL.